ArticleThe Journal of veterinary medical science2025
A case of lingual lymphoma in a dog treated with oclacitinib.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug Repurposing in Veterinary Oncology: Myth or Reality?Veterinary sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lingual canine T-zone lymphoma (TZL) is a rare form of extranodal canine lymphoma. Seven-years and 5 months old, spayed female toy poodle presented with a red swollen mass on the tongue. A punch biopsy of the lesion was conducted, followed by histopathological and immunohistochemical analyses. Despite the absence of a lymph node excisional biopsy, the case was diagnosed as canine lingual TZL. Although there is no established treatment for lingual TZL, treatment often follows TZL protocols. In this case, the tongue lesion improved after the administration of oclacitinib, a drug approved for canine atopic dermatitis. We present this case due to its successful management with oclacitinib, without the use of conventional anticancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.